免疫腫瘤治療開發的創新浪潮

下一代細胞療法和精準免疫療法推動成長和新產品開發

免疫腫瘤學 (IO) 療法透過利用宿主的免疫系統來靶向腫瘤。隨著各種類型的進行性和難治性癌症的發病率和盛行率不斷增加，下一代 IO 治療的管道正在經歷顯著成長。嵌合體標靶抗體療法，包括嵌合抗原受體（CAR）-T細胞療法、單株、抗體藥物複合體（ADC）、雙特異性抗體和一些治療性癌症疫苗，提供有效的免疫，在臨床試驗中取得了快速進展一種療法。本研究討論了推動此類 IO 治療發展的主要趨勢和技術。我們探索針對各種癌症適應症的癌症疫苗和細胞療法的進展，並重點介紹該領域的一些創新企業。也討論了下一代細胞療法、個人化癌症疫苗和戰略重點領域。這項研究檢驗了該行業的促進因素和阻礙因素，並確定了市場參與企業和相關人員應利用的該行業變化帶來的成長機會。

本次調查回答的主要問題

• 目前IO治療的臨床現況如何？
• 推動 IO 治療採用的技術推動因素是什麼？
• 過繼性細胞療法和癌症疫苗的關鍵進展是什麼？
• 臨床成功應用的障礙是什麼？
• 研究和開發的優先領域是什麼？
• 您未來的重點領域是什麼？

目錄

戰略問題

• 為什麼成長如此困難？策略要務 8 (TM)：限制成長的因素
• The Strategic Imperative 8（TM）
• 三大策略重要性對免疫腫瘤 (IO) 治療產業的影響
• 成長機會是Growth Pipeline Engine（TM）
• 調查方法

生長環境：IO處理

• 免疫治療需求
• 分析範圍
• 分段IO處理簡介
• IO治療正在開發中
• IO 治療的成長機會
• 生長促進因子
• 成長抑制因素

趨勢與研發重點：IO 治療

• IO技術的趨勢與發展
• IO 治療的趨勢
• IO治療發展趨勢
• 支持免疫療法的優先研究和開發領域
• TME 的監管：固體癌類型決定治療方法
• 發展實用化的有效臨床前模型
• IO 治療評估臨床前模型開發的相關人員
• 整體腫瘤分析加速精準腫瘤學工作

IO新療法的發展形勢

• IO 治療概述
• IO治療的臨床發展現狀
• 細胞療法推動下一波 IO 發展
• 細胞療法類型簡介
• IO細胞療法的臨床發展現狀
• 細胞療法的新重點領域，可提高功能性和安全性
• 下一代CAR-T療法的開發
• 提高細胞免疫治療可及性的優先領域
• 細胞療法製造和交付的創新技術
• 相關人員開發新的下一代細胞療法
• 疫苗應對難以治療的癌症挑戰的潛力
• 癌症疫苗的類型
• 臨床開發中的個人化新抗原疫苗
• 加強癌症疫苗研發的重點領域
• RNA疫苗正在推動預防性和治療性癌症疫苗的浪潮
• 癌症疫苗和免疫療法的未來
• 新出現的癌症疫苗
• 新興癌症疫苗對每種癌症的影響

IO相關人員生態系統

• IO 開發與採用的區域趨勢
• 加速 IO 治療開發的聯邦舉措和計劃
• IO交易及投資趨勢
• 2023 年 IO 領域著名的合作夥伴關係與聯盟

IO法規環境和報銷

• IO：當前差距和潛在機會
• 改善 IO 治療和護理服務可近性的策略

成長機會宇宙

• 成長機會1：聯合免疫治療
• 成長機會2：精準腫瘤學
• 成長機會三：先進合成生物學平台
• 成長機會4：類器官與器官晶片模型

附錄

• 核准的ADC 列表
• 核准的CAR-T 療法（全球）

下一步

Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development

Immuno-oncology (I-O) therapies target tumors by harnessing the host's immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy. This study discusses the key trends and technologies driving the development of such I-O therapies. It delves into advancements in cancer vaccines and cell therapies for various cancer indications, highlighting some of the innovators in this space. Next-generation cell therapies, personalized cancer vaccines, and strategic areas of focus have also been discussed in this report. The study examines the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.

Key questions answered in this study:

•      What does the current clinical landscape of I-O therapies look like?
•      Which are the technology enablers driving the adoption of I-O therapies?
•      What are the key developments in adoptive cell therapies and cancer vaccines?
•      What are the roadblocks to successful translation?
•      What are the research and development (R&D) focus areas?
•      What are the key focus areas for the future?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow? The strategic imperative 8™: Factors creating pressure on growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Immuno-Oncology (I-O) Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Environment: I-O Therapies

• Need for Immunotherapy
• Scope of Analysis
• Segmentation: Snapshot of I-O Therapies
• I-O Therapies in Development
• Growth Opportunities in I-O Therapy
• Growth Drivers
• Growth Restraints

Trends and R&D Focus: I-O Therapies

• I-O Technology Trends and Developments
• Trends in I-O Therapeutics
• Therapeutic Development Trends in I-O
• R&D Focus Areas to Boost Immunotherapies
• Modulation of TME: Solid Tumor Type Determines Therapy
• Developing Effective Preclinical Models for Translation
• Stakeholders Developing Preclinical Models for I-O Therapy Evaluation
• Holistic Tumor Profiling to Boost Precision Oncology Efforts

Emerging I-O Therapeutic Modality Development Landscape

• Quick Facts on I-O Therapies
• Clinical Development Landscape of I-O Therapies
• Cell Therapy to Create the Next Wave of I-O Developments
• Cell Therapy Types: Snapshot
• Clinical Development Landscape of I-O Cell Therapies
• Emerging Areas of Focus to Improve Functionality and Safety Cell Therapies
• Next-generation CAR-T Therapy Development
• Priority Areas to Improve the Accessibility of Cell Immunotherapy
• Innovative Technologies for Cell Therapy Manufacturing and Delivery
• Stakeholders Developing Emerging Next-gen Cell Therapies
• Potential of Vaccines to Address Challenges with Difficult-to-Treat Cancers
• Cancer Vaccine Types
• Personalized Neoantigen Vaccines in Clinical Development
• Areas of Focus to Bolster Cancer Vaccine Development
• RNA Vaccines to Drive the Wave of Prophylactic and Therapeutic Cancer Vaccines
• Road Ahead for Cancer Vaccines and Immunotherapy
• Emerging Cancer Vaccine
• Impact of Emerging Cancer Vaccines Across Cancers

I-O Stakeholder Ecosystem

• Regional Trends in I-O Developments and Adoption
• Federal Initiatives and Programs Driving I-O Therapy Development
• I-O Deals and Investment Trends
• Notable Partnerships and Collaborations in I-O, 2023

I-O Regulatory Environment and Reimbursement

• I-O: Current Gaps and Potential Opportunities
• Strategies to Improve Access and Care Delivery of I-O Therapies

Growth Opportunity Universe

• Growth Opportunity 1: Combination Immunotherapies
• Growth Opportunity 2: Precision Oncology
• Growth Opportunity 3: Advanced Synthetic Biology Platforms
• Growth Opportunity 4: Organoids and Organ-on-Chip Models

Appendix

• List of a Few Approved ADCs
• Approved CAR-T Therapies (global)

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer